KemPharm, Inc. (NASDAQ:KMPH) has received an average recommendation of “Buy” from the six ratings firms that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $9.00.

KMPH has been the subject of a number of research reports. Canaccord Genuity set a $7.00 price objective on shares of KemPharm and gave the company a “buy” rating in a report on Thursday, August 10th. Oppenheimer Holdings, Inc. set a $13.00 price objective on shares of KemPharm and gave the company a “buy” rating in a report on Thursday, August 10th. ValuEngine lowered shares of KemPharm from a “sell” rating to a “strong sell” rating in a report on Saturday, July 8th. Finally, Zacks Investment Research upgraded shares of KemPharm from a “sell” rating to a “hold” rating in a report on Wednesday, July 12th.

In other news, major shareholder Delaware Street Capital Master purchased 325,888 shares of the stock in a transaction on Thursday, September 14th. The stock was purchased at an average price of $3.27 per share, for a total transaction of $1,065,653.76. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last quarter, insiders purchased 335,188 shares of company stock valued at $1,090,088. 22.80% of the stock is owned by company insiders.

A hedge fund recently raised its stake in KemPharm stock. Bank of New York Mellon Corp grew its position in shares of KemPharm, Inc. (NASDAQ:KMPH) by 17.6% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 22,854 shares of the specialty pharmaceutical company’s stock after purchasing an additional 3,414 shares during the quarter. Bank of New York Mellon Corp owned about 0.16% of KemPharm worth $112,000 as of its most recent SEC filing. 40.01% of the stock is owned by hedge funds and other institutional investors.

Shares of KemPharm (NASDAQ:KMPH) opened at $3.80 on Friday. KemPharm has a one year low of $2.45 and a one year high of $5.40. The company has a current ratio of 8.40, a quick ratio of 8.40 and a debt-to-equity ratio of -2.34.

KemPharm (NASDAQ:KMPH) last issued its quarterly earnings data on Thursday, August 10th. The specialty pharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.19. analysts expect that KemPharm will post -2.7 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “KemPharm, Inc. (KMPH) Given Consensus Recommendation of “Buy” by Brokerages” was posted by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/11/05/kempharm-inc-kmph-given-consensus-recommendation-of-buy-by-brokerages.html.

About KemPharm

KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).

Receive News & Ratings for KemPharm Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm Inc. and related companies with MarketBeat.com's FREE daily email newsletter.